21.32USDMkt Cap: 3.65B USDP/E: 9.65Last update: 2026-05-21
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a se…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap3.65B USD
Enterprise Value2.85B USD
Revenue (TTM)1.10B USD
Gross Profit982.51M USD
Net Income (TTM)391.00M USD
Revenue/Share6.470 USD
Last Price21.32 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees796
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0042251084
Valuation
P/E (Trailing)9.65
P/E (Forward)23.88
PEG50.86
EV/EBITDA30.74
EV/Revenue2.60
P/S3.33
P/B2.92
EPS (TTM)2.21
EPS (Forward)0.89
52W Range
20.4186% of range21.47
52W High21.47 USD
52W Low20.41 USD
Profitability
Gross Margin91.69%
Oper. Margin-1.72%
EBITDA Margin8.46%
Profit Margin36.49%
ROE31.86%
ROA25.00%
Growth
Revenue Growth9.70%
Earnings Growth-81.80%
Cash Flow & Leverage
Operating CF109.84M USD
CapEx (TTM)4.69M USD
FCF Margin14.07%
FCF Yield4.22%
Net Debt-800.66M USD
Net Debt/EBITDA-8.64
Balance Sheet
Debt/Equity0.04
Current Ratio3.59
Quick Ratio3.27
Book Value/Sh7.295 USD
Cash/Share4.972 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)31.65 USD
Target Range17.00 USD – 45.00 USD
# Analysts20
Ownership
Shares Out.171.24M
Float127.25M
Insiders0.33%
Institutions99.07%
Short Interest
Short Ratio6.4d
Short % Float10.33%
Short % Out.6.52%
Shares Short11.16M
Short (prev mo.)10.64M
Technical
SMA 5021.71 (-1.8%)
SMA 20023.65 (-9.9%)
Beta0.86
S&P 52W Chg28.31%
Avg Vol (30d)1.61M
Avg Vol (10d)1.71M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—